GemVax & Kael announced on June 10 that a study detailing the therapeutic mechanism of its Alzheimer’s disease drug candidate, GV1001, has been published in the latest issue of Experimental & Molecular Medicine, a prestigious SCIE-indexed international journal.
The paper demonstrates that an eight-week administration of GV1001 in an Alzheimer’s disease animal model significantly reduced amyloid plaques—abnormal clumps of toxic amyloid beta (Aβ) proteins that accumulate between brain neurons. The researchers also observed notable improvements in memory and the recovery of lost synapses. Furthermore, the study confirmed that GV1001 effectively crosses the blood-brain barrier (BBB) to act directly within the brain.
According to the study, GV1001 does not work by suppressing the production of amyloid beta itself. Instead, it recruits microglia—the resident immune cells of the brain—to the site of the plaques to clear them. This clearance effect was particularly pronounced with larger plaques, which mobilized a greater concentration of immune cells, subsequently leading to a reduction in neuroinflammatory responses. Essentially, the treatment directs the brain's natural "cleanup cells" to target and dismantle pre-existing protein accumulations.
Genetic analysis revealed that GV1001 shifts microglia into a highly activated state known as disease-associated microglia stage 2 (DAM2). In this stage, the cells exhibit an enhanced ability to migrate toward amyloid plaques and a heightened capacity for phagocytosis—the process of engulfing and breaking down toxic proteins. The researchers concluded that GV1001 drives plaque clearance precisely by promoting this cellular transition.
At the molecular level, the study mapped the specific signaling pathway involved. GV1001 binds directly to bradykinin receptor 1 (B1R), which activates the mTORC2-AKT1 signaling pathway, thereby accelerating microglial migration and boosting phagocytic activity.
"This study is a meaningful achievement that newly elucidates a potential pathway of action for GV1001 in Alzheimer’s disease," a GemVax official said. "Directly removing toxic proteins using the brain's own immune cells and easing neuroinflammation represents a completely different mechanism from existing therapies, reinforcing GV1001’s differentiated competitiveness as a multi-mechanism drug."
Experimental & Molecular Medicine is an international journal jointly published by the global academic publisher Nature Portfolio and the Korean Society for Biochemistry and Molecular Biology. The study, titled "A human telomerase reverse transcriptase-derived peptide GV1001 rescues neurodegeneration in a mouse model of Alzheimer disease," was led by a research team under Professor Yoo Sung-woon at the Daegu Gyeongbuk Institute of Science and Technology (DGIST).
